Home » Topics » BioWorld Science

BioWorld Science
RSS

HPN-328 targeting DLL3 shows preclinical efficacy and safety for immunotherapy in SCLC

Nov. 18, 2019

Roche presents first-in-human data for RO-7062931

Nov. 18, 2019

resTORbio stops development of RTB-101 for clinically symptomatic respiratory illness

Nov. 15, 2019

Interim data presented from phase I study of TK-216 in Ewing's sarcoma

Nov. 15, 2019

FDA grants accelerated approval to Brukinsa for mantle cell lymphoma

Nov. 15, 2019

FDA approves Fetroja for complicated urinary tract infections

Nov. 15, 2019

I-Mab obtains Chinese IND clearance for phase I trials of TJM-2 in rheumatoid arthritis

Nov. 15, 2019

Phase II study of AV-101 in major depressive disorder does not meet primary endpoint

Nov. 15, 2019

Results from SILK cohort evaluating tesevatinib in ADPKD patients presented at Kidney Week

Nov. 15, 2019

New IDO-1 inhibitors identified at Phenex Discovery Verwaltungs

Nov. 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...